Contrasting Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (ZOM) & Its Rivals

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE: ZOM) is one of 541 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its competitors? We will compare Zomedica Pharmaceuticals Corp (NYSEAMERICAN) to related businesses based on the strength of its dividends, institutional ownership, profitability, earnings, risk, valuation and analyst recommendations.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zomedica Pharmaceuticals Corp (NYSEAMERICAN) 0 0 0 0 N/A
Zomedica Pharmaceuticals Corp (NYSEAMERICAN) Competitors 4423 12693 27221 955 2.55

As a group, “Pharmaceutical preparations” companies have a potential upside of 47.74%. Given Zomedica Pharmaceuticals Corp (NYSEAMERICAN)’s competitors higher possible upside, analysts plainly believe Zomedica Pharmaceuticals Corp (NYSEAMERICAN) has less favorable growth aspects than its competitors.

Insider and Institutional Ownership

15.6% of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) shares are held by institutional investors. Comparatively, 47.1% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 57.3% of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) shares are held by company insiders. Comparatively, 14.7% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Zomedica Pharmaceuticals Corp (NYSEAMERICAN) and its competitors gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Zomedica Pharmaceuticals Corp (NYSEAMERICAN) N/A -$16.65 million -3.56
Zomedica Pharmaceuticals Corp (NYSEAMERICAN) Competitors $2.23 billion $232.13 million -4.02

Zomedica Pharmaceuticals Corp (NYSEAMERICAN)’s competitors have higher revenue and earnings than Zomedica Pharmaceuticals Corp (NYSEAMERICAN). Zomedica Pharmaceuticals Corp (NYSEAMERICAN) is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Zomedica Pharmaceuticals Corp (NYSEAMERICAN) and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Zomedica Pharmaceuticals Corp (NYSEAMERICAN) N/A -446.39% -309.37%
Zomedica Pharmaceuticals Corp (NYSEAMERICAN) Competitors -1,871.67% -125.77% -26.56%

Volatility & Risk

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500. Comparatively, Zomedica Pharmaceuticals Corp (NYSEAMERICAN)’s competitors have a beta of 1.36, indicating that their average share price is 36% more volatile than the S&P 500.

Summary

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) competitors beat Zomedica Pharmaceuticals Corp (NYSEAMERICAN) on 7 of the 10 factors compared.

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) Company Profile

Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company's lead drug product candidate is ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs. It is also developing ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. The company has a collaboration agreement with Celsee Diagnostics, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. Zomedica Pharmaceuticals Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.

Receive News & Ratings for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) and related companies with MarketBeat.com's FREE daily email newsletter.